The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 401–500 of 748
Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy
O’Reilly, A., & Larkin, J. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1341315 · Cited by 19
Cao, K., Ma, T., Ling, X., Liu, M.-D., Jiang, X., Ma, K.-R., Zhu, J.-H., & Ma, J.-Q. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5217 · Cited by 9
van Akkooi, A. C. J., Mandalà, M., Nathan, P., Haydon, A. M., Postow, M. A., & Rutkowski, P. L. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100021 · Cited by 17
Lapuente-Santana, Ó., Sturm, G., Kant, J. A., Außerhofer, M., Zackl, C., Zopoglou, M., McGranahan, N., Rieder, D., Trajanoski, Z., de Miranda, N. F. C. C., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110529 · Cited by 19
Awakening immunity against cancer: a 2017 primer for clinicians
Jain, A., Zhang, Q., & Toh, H.-C. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0233-4 · Cited by 16
How to evaluate the immune status of lung cancer patients before immunotherapy
Domagala-Kulawik, J. J., & Raniszewska, A. (2017) · Breathe · doi:10.1183/20734735.001917 · Cited by 20
In situ administration of cytokine combinations induces tumor regression in mice
Zhang, J., Jiang, H., & Zhang, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.050 · Cited by 16
Biomarkers of immunotherapy response in breast cancer beyond PD-L1
Chic, N., Brasó‐Maristany, F., & Prat, A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06421-2 · Cited by 18
Xia, D., Casanova, R., Machiraju, D., McKee, T. D., Weder, W., Beck, A. H., & Soltermann, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-22254-4 · Cited by 17
Defining the immunogram of breast cancer: a focus on clinical trials
Tarantino, P., & Curigliano, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1598372 · Cited by 16
Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications
Peshin, S., Bashir, F., Kodali, N. A., Dharia, A. A., Zaiter, S., Singal, S., & Moka, N. (2025) · Antibodies · doi:10.3390/antib14030058 · Cited by 18
“Cold” colorectal cancer faces a bottleneck in immunotherapy
Liu, J., Yang, M., Bai, J., Liu, Z., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.240 · Cited by 23
Buma, A. I. G., Piet, B., ter Heine, R., & van den Heuvel, M. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274532 · Cited by 17
Kulesza, A. J., Couty, C., Lemarre, P., Thalhauser, C. J., & Cao, Y. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09930-x · Cited by 19
Sang, M., Ge, J., Ge, J., Tang, G., Wang, Q., Wu, J., Mao, L., Ding, X., & Zhou, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382842 · Cited by 18
Towards a better cancer precision medicine: Systems biology meets immunotherapy
Bhinder, B., & Elemento, O. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.01.006 · Cited by 17
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials
Tsao, M., Carbone, M., Galateau-Sallé, F., Moreira, A. L., Nicholson, A. G., Roden, A. C., Adjei, A. A., Aubry, M.-C., Fennell, D. A., Gomez, D. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.020 · Cited by 15
Venkatesh, B., Shah, T., Chen, A., & Ghafurian, S. (2020) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi45749.2020.9098358 · Cited by 15
Borm, F. J., Smit, J., Oprea‐Lager, D. E., Wondergem, M., Haanen, J. B. A. G., Smit, E. F., & de Langen, A. J. (2021) · Cancers · doi:10.3390/cancers13123083 · Cited by 15
Ramlee, S., Hulse, D., Bernatowicz, K., Pérez-López, R., Sala, E., & Aloj, L. (2022) · Cancers · doi:10.3390/cancers14153656 · Cited by 18
Nabbi, A., Danesh, A., Espin‐Garcia, O., Pedersen, S., Wellum, J., Fu, L. H., Paulson, J. N., Geoerger, B., Marshall, L. V., Trippett, T. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00534-x · Cited by 21
Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer
Heigener, D. F., Kerr, K. M., Laing, G. M., Mok, T. S. K., Moiseyenko, F. V., & Reck, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1894 · Cited by 16
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 17
Tailoring precision immunotherapy: coming to a clinic soon?
Han, S., Shuen, T. W. H., Wang, W.-W., Nazim, E., & Toh, H. C. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000631 · Cited by 17
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy
Chiffelle, J., Genolet, R., Michielin, O. A., & Harari, A. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101076 · Cited by 17
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
Raufi, A. M., & Tirona, M. T. (2017) · Cancer Management and Research · doi:10.2147/cmar.s111673 · Cited by 14
Chai, R., Fan, Y., Zhao, J., He, F., Li, J., & Han, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4297 · Cited by 13
Endothelial cell-derived Apelin inhibits tumor growth by altering immune cell localization
Hu, L., Hayashi, Y., Kidoya, H., & Takakura, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-93619-5 · Cited by 17
Turning up the heat: CTLA4 blockade in urothelial cancer
Stockem, C. F., Galsky, M. D., & van der Heijden, M. S. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00801-7 · Cited by 17
Mason, M., Lapuente-Santana, Ó., Halkola, A. S., Wang, W., Mall, R., Xu, X., Kaufman, J. M., Fu, J., Pfeil, J., Banerjee, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04705-3 · Cited by 15
Pei, F., He, W., Duan, Y., Yao, Q., Zhao, Y., Fan, X., Liu, S., Chen, H., He, F., Liu, T., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7224 · Cited by 16
ASCO 2018 NSCLC highlights—combination therapy is key
Gamerith, G., Kocher, F., Rudzki, J. D., & Pircher, A. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0444-7 · Cited by 14
Fonseca, I. B., Lindote, M. V. N., Monteiro, M. R., Filho, E. D., Pinto, C. A. L., Jafelicci, A. S., Lobo, M. D. M., Calsavara, V. F., Bertolli, E., & Neto, J. P. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08959-9 · Cited by 15
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers
Contos, G., Baca, Y., Xiu, J., Brown, J., Holloway, R., Korn, W. M., Herzog, T. J., Jones, N., & Winer, I. S. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.09.011 · Cited by 16
Network science in clinical trials: A patient-centered approach
Manem, V. S., Salgado, R., Aftimos, P. G., Sotiriou, C. P., & Haibe‐Kains, B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.006 · Cited by 15
Liu, W.-R., Tian, M., Tang, Z., Fang, Y., Zhou, Y., Song, S., Jiang, X., Wang, H., Tao, C., Zhou, P., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0864-0 · Cited by 16
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
Wessels, S., Muley, T., Christopoulos, P., Meister, M. A., Heinzmann-Groth, I., Warth, A., Herpel, E., Hummler, S., Klingmüller, U., Kuon, J., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-137 · Cited by 16
Zahoor, H., & Grivas, P. D. (2018) · European Urology · doi:10.1016/j.eururo.2018.12.005 · Cited by 14
GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure
Jeong, H., Cho, Y.-R., Gim, J., Cha, S.-K., Kim, M., & Kang, D. R. (2024) · PLOS ONE · doi:10.1371/journal.pone.0291223 · Cited by 14
Tinsley, N., Zhou, C., Nahm, S., Rack, S., Tan, G., Lorigan, P. C., Blackhall, F. H., & Cook, N. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100430 · Cited by 14
Fukui, T., Hosotani, S., Soda, I., Ozawa, T., Kusuhara, S., Kakegawa, M., Kasajima, M., Hiyoshi, Y., Igawa, S., Yokoba, M., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13357 · Cited by 13
The tumor microenvironment: Thousand obstacles for effector T cells
Massa, C., & Seliger, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.004 · Cited by 16
Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math
Giordano, F. A., Veldwijk, M. R., Herskind, C., & Wenz, F. K. (2018) · Strahlentherapie und Onkologie · doi:10.1007/s00066-018-1341-z · Cited by 13
Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view
Penault-Llorca, F. M., & Radosevic‐Robin, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.26 · Cited by 13
Cha, Y. J., Kim, D., Bae, S. J., Ahn, S. G., Jeong, J., Lee, H. S., Jeon, S., Yoo, T.-K., Park, W. C., & Yoon, C. I. (2021) · Scientific Reports · doi:10.1038/s41598-021-97250-2 · Cited by 13
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Chatwal, M. S., Chahoud, J., & Spiess, P. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.09 · Cited by 12
Can Systems Biology Advance Clinical Precision Oncology?
Rocca, A., & Kholodenko, B. Ν. (2021) · Cancers · doi:10.3390/cancers13246312 · Cited by 16
Chemotherapy Dose Shapes the Expression of Immune-Interacting Markers on Cancer Cells
Najibi, A. J., Larkin, K. A., Feng, Z., Jeffreys, N. C., Dacus, M. T., Rustagi, Y., Hodi, F. S., & Mooney, D. J. (2022) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-022-00742-y · Cited by 15
Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review
He, W., Li, Q., & Li, X. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103885 · Cited by 12
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study
Calura, E., Ciciani, M., Sambugaro, A., Paracchini, L., Benvenuto, G., Milite, S., Martini, P. G. V., Beltrame, L., Zane, F., Fruscio, R., et al. (2019) · Cells · doi:10.3390/cells8121554 · Cited by 12
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Mazzarella, L., Morganti, S., Marra, A., Trapani, D., Tini, G., Pelicci, P. G., & Curigliano, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000475 · Cited by 14
Milenova, I. E., González, M. L., Quixabeira, D. C. A., Santos, J. M., Cervera-Carrascón, V., Dong, W., Hemminki, A., van Beusechem, V. W., van de Ven, R., & de Gruijl, T. D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.277 · Cited by 12
Wei, S., Lu, K., Xing, J., & Yu, W. (2023) · The FASEB Journal · doi:10.1096/fj.202201022rrr · Cited by 16
Challenges faced when identifying patients for combination immunotherapy
Ernstoff, M. S., Gandhi, S., Pandey, M. R., Puzanov, I. J., Grivas, P. D., Montero, A. J., Velcheti, V., Turk, M. J., Diaz-Montero, C. M., Lewis, L. D., et al. (2017) · Future Oncology · doi:10.2217/fon-2017-0218 · Cited by 15
Hu, Y., Sun, H., Zhang, H., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01189 · Cited by 12
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response
Rico, G. T., Townsend, A. R., Price, T. J., & Patterson, K. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-236242 · Cited by 12
Bando, Y., Furukawa, J., Okamura, Y., Hara, T., Terakawa, T., Nakano, Y., & Fujisawa, M. (2022) · Anticancer Research · doi:10.21873/anticanres.15557 · Cited by 12
Domagala-Kulawik, J. J., Kwiecień, I., Pankowski, J., Pasieka-Lis, M., Wołosz, D., & Zieliński, M. (2017) · BioMed Research International · doi:10.1155/2017/5185034 · Cited by 12
Melanoma proteomics suggests functional differences related to mutational status
Trilla‐Fuertes, L., Gámez‐Pozo, A., Prado-Vázquez, G., Zapater‐Moros, A., Díaz‐Almirón, M., Fortes, C., Ferrer-Gómez, M., López‐Vacas, R., Blanco, V. P., Márquez‐Rodas, I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43512-z · Cited by 13
Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer
Morris, L. G. T. (2023) · The Laryngoscope · doi:10.1002/lary.30761 · Cited by 11
Brummer, O., Pölönen, P., Mustjoki, S. M., & Brück, O. E. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02329-4 · Cited by 22
Schuiveling, M., ter Maat, L. S., van Duin, I. A. J., Verheijden, R. J., Troenokarso, M. F., Moeskops, P., Verhoeff, J. J. C., Elias, S. G., van Amsterdam, W. A. C., Burgers, F. H., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf039 · Cited by 15
Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
Petrelli, F., Consoli, F., Ghidini, A., Perego, G., Luciani, A., Mercurio, P., Berruti, A., & Grisanti, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720748 · Cited by 11
Yang, J., Shi, W., Yang, Z., Yu, H., Wang, M., Wei, Y., Wen, J., Zheng, W., Zhang, P., Zhao, W., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-171 · Cited by 14
Can C-Reactive Protein (CRP) Time Series Forecasting be Achieved via Deep Learning?
Dorraki, M., Fouladzadeh, A., Salamon, S. J., Allison, A., Coventry, B. J., & Abbott, D. (2019) · IEEE Access · doi:10.1109/access.2019.2914473 · Cited by 12
Overview of Basic Immunology and Clinical Application
Stephen, B., & Hajjar, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_1 · Cited by 13
Targeting the immune milieu in gastrointestinal cancers
Turkes, F., Mencel, J., & Starling, N. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01710-x · Cited by 11
The future of combination therapies in advanced melanoma
Höeller, C. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00640-x · Cited by 11
Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors
Villanueva-Fernández, E., Hermsen, M. A. J. A., Suárez–Fernández, L., Vivanco, B., Franchi, A., García‐Marín, R., Cabal, V. N., Codina‐Martínez, H., Lorenzo‐Guerra, S. L., Llorente, J. L., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092205 · Cited by 14
Sunakawa, Y., Inoue, E., Matoba, R., Kawakami, H., Sato, Y., Nakajima, T. E., Muro, K., Ichikawa, W., & Fujii, M. (2019) · Future Oncology · doi:10.2217/fon-2019-0167 · Cited by 11
Harmonizing PD-L1 testing in metastatic triple negative breast cancer
Giugliano, F., Antonarelli, G., Tarantino, P., Cortés, J., Rugo, H. S., & Curigliano, G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2021180 · Cited by 11
Liu, Z., Xun, J., Liu, S., Wang, B., Zhang, A., Zhang, L., Wang, X., & Zhang, Q. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.10.003 · Cited by 12
Benzekry, S., Karlsen, M., Bigarré, C., Kaoutari, A. E., Gomes, B., Stern, M., Neubert, A., Bruno, R., Mercier, F., Vatakuti, S., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3371 · Cited by 15
Insights into breast cancer phenotying through molecular omics approaches and therapy response
Belizário, J. E., & Loggulo, A. F. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.009 · Cited by 15
La biologie des cibles PD-1 et CTLA-4 et la question des biomarqueurs
Dieu‐Nosjean, M., & Caux, C. (2019) · médecine/sciences · doi:10.1051/medsci/2019192 · Cited by 20
Bates, A. M., Lanzel, E. A., Fang, Q., Abbasi, T., Vali, S., & Brogden, K. A. (2017) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2017.05.474 · Cited by 13
Passenger mutations in cancer evolution
Aparisi, F., Labrador, H. A., Fariñas, S. C., Torres‐Martínez, S., Herreros‐Pomares, A., Lewintre, E. J., Blasco, A. V., Iranzo, V., & Camps, C. (2019) · Cancer Reports and Reviews · doi:10.15761/crr.1000188 · Cited by 14
Understanding resistance to immune checkpoint inhibitors in advanced breast cancer
Tarantino, P., Barroso‐Sousa, R., Garrido-Castro, A. C., McAllister, S. S., Guerriero, J. L., Mittendorf, E. A., Curigliano, G., & Tolaney, S. M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2020650 · Cited by 10
Karime, C., Wang, J., Woodhead, G. J., Mody, K., Hennemeyer, C. T., Borad, M. J., Mahadevan, D., Chandana, S. R., & Babiker, H. M. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2019706 · Cited by 10
Jou, J., Kato, S., Miyashita, H., Thangathurai, K., Pabla, S., DePietro, P., Nesline, M., Conroy, J. M., Rubin, E., Eskander, R. N., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0270 · Cited by 10
A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy
Bertolli, E., de Macêdo, M. P., Calsavara, V. F., Pinto, C. A. L., & Neto, J. P. D. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.10.060 · Cited by 12
Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers
Dollinger, E., Bergman, D. R., Zhou, P., Atwood, S. X., & Nie, Q. H. (2020) · Cancers · doi:10.3390/cancers12102946 · Cited by 11
Resisting resistance to cancer immunotherapy
Lam, S. T., Wang, L. Z., Roudi, R., Yong, W. P., Syn, N. L. X., & Sundar, R. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12614 · Cited by 10
Koh, J., Lee, D., Kim, S., Song, S. G., Han, B., Jeong, H., Kim, Y. A., Keam, B., Lee, S., Kim, K., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0071 · Cited by 9
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment
Lopez, S. H., Jalving, M., Fehrmann, R. S. N., Nagengast, W. B., de Vries, E. G. E., & de Haan, J. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102406 · Cited by 9
The journey of F1000Research since inception: through bibliometric analysis
Kumar, D., Shandilya, A. K., & Srivastava, S. (2023) · F1000Research · doi:10.12688/f1000research.134244.2 · Cited by 10
PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression
Brogden, K. A., Vali, S., & Abbasi, T. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.12.43 · Cited by 9
Discovery and application of immune biomarkers for hematological malignancies
Zafeiris, D., Vadakekolathu, J. N., Wagner, S., Pockley, A. G., Ball, G., & Rutella, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1381560 · Cited by 9
PD-1 antibodies in head-and-neck cancer
Wollenberg, B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32346-8 · Cited by 9
Masuda, T., Noda, M., Kitagawa, A., Hu, Q., Fujii, A., Ito, S., Kosai, K., ANDO, Y., Matsumoto, Y., Ohtsu, H., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14362 · Cited by 9
Prognostic value of immune-related genes in laryngeal squamous cell carcinoma
Liu, W., Zhang, C., Gong, X., Liao, W., Xu, J., & Zhang, X. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2173 · Cited by 9
Personalised Precision Medicine - A Novel Approach for Oral Cancer Management
Patil, D. J., & Nagaraju, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99558 · Cited by 11
Ferrari, N., Ward, G. A., Gewinner, C. A., Davis, M. P. A., Jueliger, S., Saini, H. K., Munck, J. M., Smyth, T., Ferraldeschi, R., Keer, H. N., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003955 · Cited by 10
The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients
Hirsch, F. R., Walker, J., Higgs, B. W., Cooper, Z. A., Raja, R. G., & Wistuba, I. I. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.011 · Cited by 10
Saidak, Z., Louandre, C., Dahmani, S., Sauzay, C., Guedda, S., Chauffert, B., Chatelain, D., Ceballos-Picot, I., & Galmiche, A. (2018) · Bioscience Reports · doi:10.1042/bsr20171716 · Cited by 11
Is single versus combination therapy problematic in the treatment of cutaneous melanoma?
Krattinger, R., Ramelyte, E., Dornbierer, J., & Dummer, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1650641 · Cited by 10
Hofving, T., Liang, F., Karlsson, J. W., Yrlid, U., Nilsson, J. A., Nilsson, O., & Nilsson, L. M. (2021) · Cancers · doi:10.3390/cancers13174305 · Cited by 9
Cao, Y., Zhao, Z., Fang, J., Lu, Y., Huang, Z., Wu, G., Gao, Q., Li, R., Xu, L., & Xu, X. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500646 · Cited by 8
Zervanos, D.-I., Galatou, E., Miliotou, Α. N., Theodoroula, N. F., Grigoriadis, N., & Vizirianakis, I. S. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030043 · Cited by 8
Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer
Syeda, M. F., Santos, R. A., Sousa, L. M., Paiva, A. R., Branco, N. C., Pereira, T. C., Sousa, G., & Rodrigues‐Santos, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1654748 · Cited by 10
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.